Abstract
Carnitine palmitoyltransferase 2 (CPTII) deficiency is among the most common inborn errors of mitochondrial fatty acid β-oxidation (FAO). Clinical phenotype varies in relation to the metabolic block, as assessed by studies of FAO in patient fibroblasts. Thus, fibroblasts from patients with mild manifestations have appreciable residual CPTII enzyme activity, in contrast to those from severely affected patients. In the present study, we hypothesized that the hypolipidemic drug bezafibrate, acting as an activator of the peroxisome proliferator-activated receptor α might stimulate FAO in CPTII-deficient cells. Data obtained show that bezafibrate treatment of mild-type CPTII-deficient cells resulted in a time- and dose- dependant increase in CPTII mRNA (from +47% to +66%) and residual enzyme activity (from +54% to 135%), and led to normalization of 3H-palmitate and 3H-myristate cellular oxidation rates. Bezafibrate did not correct FAO in fibroblasts from patients with severe phenotype. This study establishes for the first time that peroxisome proliferator-activated receptor activators, acting via stimulation of gene expression, can stimulate CPTII residual activity to a level sufficient to allow normal FAO flux in deficient human fibroblasts, and suggests that this approach should be tested in other inborn errors of mitochondrial β-oxidation.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
Abbreviations
- FAO:
-
mitochondrial fatty acid β-oxidation
- CPTII:
-
carnitine palmitoyltransferase 2
- CPTI:
-
carnitine palmitoyltransferase 1
- PPARα:
-
peroxisome proliferator-activated receptor α
- LCFA:
-
long-chain fatty acid
References
Bonnefont JP, Demaugre F, Prip-Buus C, Saudubray JM, Brivet M, Abadi N, Thuillier L 1999 Carnitine palmitoyltransferase deficiencies. Mol Genet Metab 68: 424–440
Gregersen N, Andresen BS, Corydon MJ, Corydon TJ, Olsen RK, Bolund L, Bross P 2001 Mutation analysis in mitochondrial fatty acid oxidation defects: exemplified by acyl-CoA dehydrogenase deficiencies, with special focus on genotype-phenotype relationship. Hum Mutat 18: 169–189
Brivet M, Boutron A, Slama A, Costa C, Thuillier L, Demaugre F, Rabier D, Saudubray JM, Bonnefont JP 1999 Defects in activation and transport of fatty acids. J Inherit Metab Dis 22: 428–441
Bonnefont JP, Taroni F, Cavadini P, Cepanec C, Brivet M, Saudubray JM, Leroux JP, Demaugre F 1996 Molecular analysis of carnitine palmitoyltransferase II deficiency with hepatocardiomuscular expression. Am J Hum Genet 58: 971–978
Berger J, Moller DE 2002 The mechanisms of action of PPARs. Annu Rev Med 53: 409–435
Vamecq J, Latruffe N 1999 Medical significance of peroxisome proliferator-activated receptors. Lancet 354: 141–148
Thuillier L, Rostane H, Droin V, Demaugre F, Brivet M, Khadom N, Prip-Buus C, Gobin S, Saudubray JM, Bonnefont JP 2003 Correlation between genotype, metabolic data, and clinical presentation in carnitine palmitoyltransferase 2 deficiency. Hum Mutat 5: 493–501
Demaugre F, Bonnefont JP, Colonna M, Cepanec C, Leroux JP, Saudubray JM 1991 Infantile form of carnitine palmitoyltransferase II deficiency with hepatomuscular symptoms and sudden death. Physiopathological approach to carnitine palmitoyltransferase II deficiencies. J Clin Invest 87: 859–864
Manning NJ, Olpin SE, Pollitt RJ, Webley J 1990 A comparison of [9,10–3H]palmitic and [9,10–3H]myristic acids for the detection of defects of fatty acid oxidation in intact cultured fibroblasts. J Inherit Metab Dis 13: 58–68
Lowry OH, Rosebrough NJ, Farr AL, Randall RJ 1951 Protein measurement with the folin phenol reagent. J Biol Chem 193: 265–275
Eaton S 2002 Control of mitochondrial beta-oxidation flux. Prog Lipid Res 41: 197–239
Brandt JM, Djouadi F, Kelly DP 1998 Fatty acids activate transcription of the muscle carnitine palmitoyltransferase I gene in cardiac myocytes via the peroxisome proliferator-activated receptor alpha. J Biol Chem 273: 23786–23792
Mascaro C, Acosta E, Ortiz JA, Marrero PF, Hegardt FG, Haro D 1998 Control of human muscle-type carnitine palmitoyltransferase I gene transcription by peroxisome proliferator-activated receptor. J Biol Chem 273: 8560–8563
Gulick T, Cresci S, Caira T, Moore DD, Kelly DP 1994 The peroxisome proliferator-activated receptor regulates mitochondrial fatty acid oxidative enzyme gene expression. Proc Natl Acad Sci U S A 91: 11012–11016
Ouali F, Djouadi F, Merlet-Benichou C, Bastin J 1998 Dietary lipids regulate beta-oxidation enzyme gene expression in the developing rat kidney. Am J Physiol 275: F777–F784
Yu GS, Lu YC, Gulick T 1998 Co-regulation of tissue-specific alternative human carnitine palmitoyltransferase Ibeta gene promoters by fatty acid enzyme substrate. J Biol Chem 273: 32901–32909
Muoio DM, Way JM, Tanner CJ, Winegar DA, Kliewer SA, Houmard JA, Kraus WE, Dohm GL 2002 Peroxisome proliferator-activated receptor-alpha regulates fatty acid utilization in primary human skeletal muscle cells. Diabetes 51: 901–909
Watanabe K, Fujii H, Takahashi T, Kodama M, Aizawa Y, Ohta Y, Ono T, Hasegawa G, Naito M, Nakajima T, Kamijo Y, Gonzalez FJ, Aoyama T 2000 Constitutive regulation of cardiac fatty acid metabolism through peroxisome proliferator-activated receptor alpha associated with age-dependent cardiac toxicity. J Biol Chem 275: 22293–22299
Aoyama T, Peters JM, Iritani N, Nakajima T, Furihata K, Hashimoto T, Gonzalez FJ 1998 Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor alpha (PPARalpha). J Biol Chem 273: 5678–5684
Barrero MJ, Camarero N, Marrero PF, Haro D 2003 Control of human carnitine palmitoyltransferase II gene transcription by peroxisome proliferator-activated receptor through a partially conserved PPRE. Biochem J 369: 721–729
Taroni F, Verderio E, Fiorucci S, Cavadini P, Finocchiaro G, Uziel G, Lamantea E, Gellera C, DiDonato S 1992 Molecular characterization of inherited carnitine palmitoyl transferase II deficiency. Proc Natl Acad Sci U S A 89: 8429–8433
Acknowledgements
The authors thank Mrs. D. Muscat (Sigma-Tau France) for providing us with l-aminocarnitine. We also thank Laurie Laugier for technical assistance.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supported, in part, by a grant from the Association Française contre les Myopathies.
Rights and permissions
About this article
Cite this article
Djouadi, F., Bonnefont, JP., Thuillier, L. et al. Correction of Fatty Acid Oxidation in Carnitine Palmitoyl Transferase 2–Deficient Cultured Skin Fibroblasts by Bezafibrate. Pediatr Res 54, 446–451 (2003). https://doi.org/10.1203/01.PDR.0000083001.91588.BB
Received:
Accepted:
Issue date:
DOI: https://doi.org/10.1203/01.PDR.0000083001.91588.BB
This article is cited by
-
Mitochondrial membrane transporters and metabolic switch in heart failure
Heart Failure Reviews (2019)
-
Carnitine palmitoyl transferase 2 polymorphism may be associated with enterovirus 71 severe infection in a Chinese population
Archives of Virology (2016)
-
Mitochondrial trifunctional protein deficiency in human cultured fibroblasts: effects of bezafibrate
Journal of Inherited Metabolic Disease (2016)
-
Genetic variations underlying self-reported physical functioning: a review
Quality of Life Research (2015)
-
Stilbenes and resveratrol metabolites improve mitochondrial fatty acid oxidation defects in human fibroblasts
Orphanet Journal of Rare Diseases (2014)
